Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum

Cécile Crosnier, Leyla Y. Bustamante, S. Josefin Bartholdson, Amy K. Bei, Michel Theron, Makoto Uchikawa, Souleymane Mboup, Omar Ndir, Dominic P. Kwiatkowski, Manoj T. Duraisingh, Julian C. Rayner () and Gavin J. Wright ()
Additional contact information
Cécile Crosnier: Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Hinxton
Leyla Y. Bustamante: Malaria Programme, Wellcome Trust Sanger Institute, Hinxton
S. Josefin Bartholdson: Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Hinxton
Amy K. Bei: Harvard School of Public Health
Michel Theron: Malaria Programme, Wellcome Trust Sanger Institute, Hinxton
Makoto Uchikawa: Tokyo Red Cross Blood Center
Souleymane Mboup: Laboratory of Bacteriology and Virology, Le Dantec Hospital and Laboratory of Parasitology, Cheikh Anta Diop University, BP: 7325
Omar Ndir: Laboratory of Bacteriology and Virology, Le Dantec Hospital and Laboratory of Parasitology, Cheikh Anta Diop University, BP: 7325
Dominic P. Kwiatkowski: Malaria Programme, Wellcome Trust Sanger Institute, Hinxton
Manoj T. Duraisingh: Harvard School of Public Health
Julian C. Rayner: Malaria Programme, Wellcome Trust Sanger Institute, Hinxton
Gavin J. Wright: Cell Surface Signalling Laboratory, Wellcome Trust Sanger Institute, Hinxton

Nature, 2011, vol. 480, issue 7378, 534-537

Abstract: No entry for malaria parasites The ability to prevent or impair the invasion of erythrocytes by the Plasmodium falciparum merozoite, the initial blood stage of malaria infection, has long been an ambition for those working on antimalarial therapeutics. It has proved elusive, but comes a step closer with the identification of a specific interaction between the parasite ligand PfRh5 and the erythrocyte receptor basigin, which is essential for parasite invasion of erythrocytes. Invasion can be inhibited by anti-basigin antibodies in all laboratory-adapted and field strains of P. falciparum tested, providing a promising starting point for the development of invasion-blocking drugs and vaccines.

Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/nature10606 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:480:y:2011:i:7378:d:10.1038_nature10606

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature10606

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().